BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 34157209)

  • 21. Health related quality of life is excellent and sustained at two decades after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in survivors of pseudomyxoma peritonei of appendiceal origin.
    Kung V; Delisle M; Alves S; Mohamed F; Cecil T; Moran B
    Eur J Surg Oncol; 2023 Nov; 49(11):107045. PubMed ID: 37677915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study.
    Yrjönen A; Koskenvuo L; Haapamäki C; Lepistö A
    Scand J Surg; 2024 Jun; 113(2):140-149. PubMed ID: 37828760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
    Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms.
    Abudeeb H; Selvasekar CR; O'Dwyer ST; Chakrabarty B; Malcolmson L; Renehan AG; Wilson MS; Aziz O
    Surg Endosc; 2020 Dec; 34(12):5516-5521. PubMed ID: 31993814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial?
    Huang Y; Alzahrani NA; Liauw W; Traiki TB; Morris DL
    Ann Surg Oncol; 2017 Jan; 24(1):176-183. PubMed ID: 27718032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.
    Baratti D; Kusamura S; Milione M; Pietrantonio F; Caporale M; Guaglio M; Deraco M
    Ann Surg Oncol; 2016 Dec; 23(13):4222-4230. PubMed ID: 27352203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
    Kusamura S; Barretta F; Yonemura Y; Sugarbaker PH; Moran BJ; Levine EA; Goere D; Baratti D; Nizri E; Morris DL; Glehen O; Sardi A; Barrios P; Quénet F; Villeneuve L; Gómez-Portilla A; de Hingh I; Ceelen W; Pelz JOW; Piso P; González-Moreno S; Van Der Speeten K; Deraco M;
    JAMA Surg; 2021 Mar; 156(3):e206363. PubMed ID: 33502455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of causes and prognostic impact of tube occlusion during hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei.
    Liu Q; Jiao J; Li C; Chen Y; Wang B; Shi J; Yu G
    World J Surg Oncol; 2024 May; 22(1):134. PubMed ID: 38769546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of cytoreductive surgery and HIPEC for pseudomyxoma peritonei of appendiceal origin from two Indian centers: A preliminary five-year experience.
    Bhatt A; Sheshadri D; Chandan G; Ramaswamy V; Pandey J; Bhorkar N; Agrawal D; Mehta S
    J BUON; 2017; 22(1):251-257. PubMed ID: 28365962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.
    van Eden WJ; Kok NFM; Snaebjornsson P; Jóźwiak K; Woensdregt K; Bottenberg PD; Boot H; Aalbers AGJ
    BJS Open; 2019 Jun; 3(3):376-386. PubMed ID: 31183454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety in the use of intraperitoneal hyperthermia chemotherapy and peritoneal cytoreductive surgery for pseudomyxoma peritonei from appendiceal neoplasm: A systematic review.
    Floriano I; Silvinato A; Reis JC; Cafalli C; Bernardo WM
    Clinics (Sao Paulo); 2022; 77():100039. PubMed ID: 35576869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laparoscopic cytoreductive surgery and HIPEC in LAMN with small volume of peritoneal disease: a valuable option of treatment for good patient-related experience measures (PREMs).
    Cusumano C; Carrere S; Bouillin A; Nougaret S; Khellaf L; Quénet F; Sgarbura O
    Surg Endosc; 2022 Jul; 36(7):4757-4763. PubMed ID: 34845545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
    Vaira M; Robella M; Mellano A; Sottile A; De Simone M
    Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Referral and treatment pathways for pseudomyxoma peritonei of appendiceal origin within a national treatment programme.
    Fish R; Renehan AG; Punnett G; Aziz O; Fulford P; Selvasekar C; Wilson M; Halstead R; O'Dwyer ST
    Colorectal Dis; 2018 Oct; 20(10):888-896. PubMed ID: 29920919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative systemic chemotherapy does not benefit for appendiceal pseudomyxoma peritonei.
    Ma R; Lu D; Xue S; Fan X; Zhai X; Wang C; Xu H; Pang S
    ANZ J Surg; 2023 Jan; 93(1-2):219-226. PubMed ID: 36136728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience.
    Azzam AZ; Alyahya ZA; Wusaibie AAA; Amin TM
    Indian J Gastroenterol; 2017 Nov; 36(6):452-458. PubMed ID: 29185227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
    Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
    Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Mercier F; Dagbert F; Pocard M; Goéré D; Quenet F; Wernert R; Dumont F; Brigand C; Passot G; Glehen O;
    BJS Open; 2019 Apr; 3(2):195-202. PubMed ID: 30957067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case of pseudomyxoma peritonei arising from a perforated intraductal papillary mucinous neoplasm that underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Yoshizaki Y; Gohda Y; Inagaki F; Kataoka A; Takemura N; Miyazaki H; Igari T; Kiyomatsu T; Yano H; Kokudo N
    Clin J Gastroenterol; 2024 Feb; 17(1):188-197. PubMed ID: 37980306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.